The earnings call reflected a strong performance in revenue growth and strategic initiatives, particularly in clinic expansion and adolescent patient engagement. However, challenges in gross margin and delayed positive cash flow targets indicate areas needing improvement.

Company Guidance

During the Neuronetics second quarter 2025 earnings call, the company provided a comprehensive overview of its financial performance and strategic initiatives. Total revenue for the quarter was reported at $38.1 million, marking an 18% year-over-year increase on an adjusted pro forma basis. The NeuroStar business contributed $15.1 million to this, with system revenue of $3.5 million from 41 systems shipped and U.S. treatment session revenue at $10.8 million, up 13% pro forma. U.S. clinic revenue achieved a record $23 million, driven by Greenbrook's operations. The company also reported cash usage in operations at $3.5 million, surpassing the previous guidance of under $5 million. Looking forward, Neuronetics maintained its full-year revenue guidance of $149 million to $155 million, while adjusting its gross margin expectations to between 48% and 50% due to a shift in revenue mix. The company is also targeting to achieve positive cash flow from operations by the fourth quarter of 2025, bolstered by improvements in its operational efficiencies and cash collection processes.

Record Revenue Growth

Total revenue was $38.1 million, an 18% year-over-year increase on an adjusted pro forma basis.

NeuroStar System Performance

NeuroStar system revenue was $3.5 million with 41 systems shipped, maintaining a system ASP greater than $85,000.

U.S. Clinic Revenue Achievements

U.S. clinic revenue was $23 million, marking the largest quarterly clinic revenue to date.

Cash Flow Improvement

Cash used in operations was $3.5 million, better than the previously guided target of under $5 million.

Adolescent Patient Growth

25% growth in adolescent new patient starts in the first half of 2025 compared to 2024.

SPRAVATO Rollout Momentum

SPRAVATO therapy offered in 77 of 83 eligible clinics, with full rollout expected by year-end.

Neuronetics (STIM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

STIM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.13 / -	-0.44	―	―	―
Aug 05, 2025	2025 (Q2)	-0.08 / -0.15	-0.33	54.55% (+0.18)
May 06, 2025	2025 (Q1)	-0.12 / -0.21	-0.27	22.22% (+0.06)
Mar 04, 2025	2024 (Q4)	-0.24 / -0.33	-0.19	-73.68% (-0.14)
Nov 12, 2024	2024 (Q3)	-0.23 / -0.44	-0.33	-33.33% (-0.11)
Aug 12, 2024	2024 (Q2)	-0.27 / -0.33	-0.17	-94.12% (-0.16)
May 07, 2024	2024 (Q1)	-0.31 / -0.27	-0.38	28.95% (+0.11)	―
Mar 05, 2024	2023 (Q4)	-0.26 / -0.19	-0.3	36.67% (+0.11)	―
Nov 07, 2023	2023 (Q3)	-0.31 / -0.33	-0.28	-17.86% (-0.05)	―
Aug 08, 2023	2023 (Q2)	-0.35 / -0.17	-0.39	56.41% (+0.22)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

STIM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$4.66	$4.54	-2.58%
May 06, 2025	$4.50	$4.50	0.00%
Mar 04, 2025	$4.26	$5.06	+18.78%
Nov 12, 2024	$1.10	$0.69	-37.27%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Neuronetics Inc (STIM) report earnings?

Neuronetics Inc (STIM) is schdueled to report earning on Nov 11, 2025, Before Open (Confirmed).

What is Neuronetics Inc (STIM) earnings time?

Neuronetics Inc (STIM) earnings time is at Nov 11, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is STIM EPS forecast?

STIM EPS forecast for the fiscal quarter 2025 (Q3) is -0.13.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing